Pure Global
NCT05839444

A Clinical Study to Evaluate the Safety and Tolerability of BioPB-01 in Healthy Adults

A Pilot Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Tolerability of BioPB-01 in Healthy Adults
Vedic Lifesciences Pvt. Ltd.·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metabolic Syndrome
Drug/Device/Intervention
BioPB-01
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Vedic Lifesciences Pvt. Ltd.
Location
Vadodara,Nashik, India
Timeline & enrollment
Phase
N/A
Start date
Apr 27, 2023
End date
Sep 10, 2023
Enrollment
64 participants
Primary outcome

To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on,To evaluate the safety of 21 days of BioPB-01 administration on

Summary

The present study is a randomized, placebo-controlled, parallel-group, double-blind clinical
 study. Seventy-eight individuals will be screened, and considering a screening failure rate
 of 20%, approximately 64 participants will be randomized in a ratio of 1:1 to receive either
 BioPB-01 or Placebo

ICD-10 classifications
Metabolic disordersMetabolic disorder, unspecifiedOther metabolic disordersOther specified metabolic disordersNutritional and metabolic disorders in diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05839444
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05839444 through Pure Global AI's free database. This phase not specified trial is sponsored by Vedic Lifesciences Pvt. Ltd. and is currently Recruiting. The study focuses on Metabolic Syndrome. Target enrollment is 64 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.